3SBIO(01530),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01530 3SBIO

Closed 04-28 16:08:26

22.380

+0.220

+0.99%

High22.980	Low21.920	Vol22.62M
Open22.220	D1 Closing22.160	Amplitude4.78%
Mkt Cap56.80B	Tradable Cap56.80B	Total Shares2.54B
T/O505.84M	T/O Rate0.89%	Tradable Shares2.54B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"3SBIO","latestPrice":22.38,"timestamp":1777363706005,"preClose":22.16,"halted":0,"volume":22618201,"delay":0,"changeRate":0.009927797833934967,"floatShares":2538000000,"shares":2538000000,"eps":3.92902785179148,"marketStatus":"Closed","change":0.22,"latestTime":"04-28 16:08:26","open":22.22,"high":22.98,"low":21.92,"amount":505837683,"amplitude":0.047834,"askPrice":22.38,"askSize":27000,"bidPrice":22.36,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":3.92902785179148,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1777426200000},"marketStatusCode":5,"adr":0,"listingDate":1433952000000,"exchange":"SEHK","adjPreClose":22.16,"dividendRate":0.011549,"openAndCloseTimeList":[[1777339800000,1777348800000],[1777352400000,1777363200000]],"volumeRatio":0.481584,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01530/tweets","defaultTab":"tweets","newsList":[{"id":"2629910834","title":"3SBio shareholders approved conditional Mandi share distribution at extraordinary general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629910834","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629910834?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:50","pubTimestamp":1776948604,"startTime":"0","endTime":"0","summary":"3SBio held an extraordinary general meeting on April 23, 2026.Shareholders adopted an ordinary resolution to declare and approve a conditional special dividend from share premium to be paid via an in-specie distribution of all Mandi shares held by 3SBio to qualifying shareholders.Shareholders also authorized directors to implement the distribution, including setting key terms such as record date and distribution basis.Distribution has not been executed and remains conditional on the proposed spin-off, global offering, and listing becoming unconditional.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 3SBio Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Ko","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL4QFS4b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1593","BK1161","01530","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183896738","title":"Stock Track | 3SBIO Plummets 13.14% Intraday Amid Broader Biotech Selloff as Geopolitical Tensions and Oil Prices Dampen Rate Cut Hopes","url":"https://stock-news.laohu8.com/highlight/detail?id=1183896738","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183896738?lang=en_us&edition=fundamental","pubTime":"2026-04-23 14:04","pubTimestamp":1776924291,"startTime":"0","endTime":"0","summary":"3SBIO (01530) experienced a sharp intraday decline of 13.14%, reflecting a broader downturn in the innovative drug sector during the trading session.The selloff was driven by persistent geopolitical...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105593446","title":"Biopharma Stocks Slide Across Board as Oil Prices Squeeze Rate Cut Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=1105593446","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105593446?lang=en_us&edition=fundamental","pubTime":"2026-04-23 14:02","pubTimestamp":1776924147,"startTime":"0","endTime":"0","summary":"Innovative drug stocks experienced broad declines in Hong Kong trading. At the time of writing, 3SBIO (01530) fell 12.73% to HK$21.38. REMEGEN (09995) dropped 6.86% to HK$105.9. INNOVENT BIO (01801)...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","01530","ERX","OILK","LU2097828805.USD","USOI","BNO","DUG","LU0455707207.USD","LU2242644610.SGD","LU2097828714.EUR","OIH","01801","LU1969619763.USD","LU2488822045.USD","UGA","BWET","BK4570","VDE","VXUS","USE","BK1589","159992","LU2097828474.EUR","06978","IEO","BK1574","PXJ","DBE","BK1161","03692","DBO","DRIP","DRLL","BK1583","DIG","DBC","OILT","BK1191","BK4585","LU0502904849.HKD","HK0000165453.HKD","BK1593","09995","BK4588","IXC","LU2097828557.USD","USL","OILU","LU2097828631.EUR","GUSH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133238716","title":"CMB International Reports Moderate Recovery in Healthcare Sector Risk Appetite, Recommends Six Stocks Including Hansoh Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=1133238716","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133238716?lang=en_us&edition=fundamental","pubTime":"2026-04-20 13:50","pubTimestamp":1776664224,"startTime":"0","endTime":"0","summary":"According to a research report from CMB International, the MSCI China Healthcare Index has risen 12.3% since the beginning of 2026, outperforming the MSCI China Index by 13.6%. Recent policy...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0455707207.USD","BK1589","LU2097828805.USD","BK1593","BK1141","01530","BK1574","LU2328871848.SGD","SG9999014674.SGD","BK1161","BK1191","LU2488822045.USD","01801","LU2097828631.EUR","LU2097828474.EUR","01167","LU2242644610.SGD","HK0000165453.HKD","BK1583","LU2097828714.EUR","LU0502904849.HKD","LU2097828557.USD","02268","03692","LU1969619763.USD","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129574663","title":"Stock Track | 3SBIO Soars 5.30% Intraday on Clinical Trial Approval and Institutional Endorsement","url":"https://stock-news.laohu8.com/highlight/detail?id=1129574663","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129574663?lang=en_us&edition=fundamental","pubTime":"2026-04-17 09:37","pubTimestamp":1776389864,"startTime":"0","endTime":"0","summary":"3SBIO's stock price soared 5.30% during intraday trading on Friday, reflecting significant investor interest in the biopharmaceutical company.The rally was primarily driven by the recent clinical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114842369","title":"3SBIO Shares Surge Over 9% Afternoon on Domestic Clinical Approval for SSGJ-707 in Lung and Kidney Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=1114842369","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114842369?lang=en_us&edition=fundamental","pubTime":"2026-04-15 14:38","pubTimestamp":1776235105,"startTime":"0","endTime":"0","summary":"3SBIO (01530) rose more than 9% in afternoon trading. At the time of writing, the stock was up 7.2%, trading at HK$24.7 with a turnover of HK$13.03 billion. The surge follows news that on April 7,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK4585","01530","BK1583","VXUS","BK1161","HK0000165453.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142533714","title":"Stock Track | 3SBIO Soars 5.12% Intraday on Dual IND Approval for SSS67 and Pfizer Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=1142533714","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142533714?lang=en_us&edition=fundamental","pubTime":"2026-04-15 11:51","pubTimestamp":1776225076,"startTime":"0","endTime":"0","summary":"3SBIO's stock price surged 5.12% during intraday trading on Wednesday, marking a significant upward movement.The rally appears driven by positive developments for the company's pipeline. Its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164413996","title":"Morgan Stanley Cuts 3SBIO (01530) Target Price to HK$34, Keeps \"Overweight\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1164413996","media":"Stock News","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164413996?lang=en_us&edition=fundamental","pubTime":"2026-04-14 11:40","pubTimestamp":1776138036,"startTime":"0","endTime":"0","summary":"Morgan Stanley has released a research report incorporating 3SBIO's (01530) 2025 performance forecast. The report lowers the sales forecast and milestone payment expectations for the company's core...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","EWH","HK0000165453.HKD","BK1583","BK1593","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125668655","title":"Stock Track | 3SBio Soars 5.05% Intraday on Strong 2025 Earnings and Undervaluation Appeal","url":"https://stock-news.laohu8.com/highlight/detail?id=1125668655","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125668655?lang=en_us&edition=fundamental","pubTime":"2026-04-13 13:34","pubTimestamp":1776058472,"startTime":"0","endTime":"0","summary":"3SBio's stock price surged 5.05% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.The sharp rise appears driven by the company's recently...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627328106","title":"Assessing 3SBio (SEHK:1530) Valuation After Strong 2025 Earnings And Affirmed Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2627328106","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627328106?lang=en_us&edition=fundamental","pubTime":"2026-04-13 02:11","pubTimestamp":1776017506,"startTime":"0","endTime":"0","summary":"Why 3SBio’s latest earnings and dividend decision matter\n3SBio (SEHK:1530) has drawn fresh attention after reporting full year 2025 results alongside a reaffirmed final dividend. This combination puts both profitability and cash returns to shareholders in focus.\nThe company reported sales of CNY 17,695.75 million and net income of CNY 8,482.16 million for 2025, with basic earnings per share from continuing operations at CNY 3.51 and diluted earnings per share at CNY 3.43.\nSee our latest...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/assessing-3sbio-sehk1530-valuation-after-strong-2025-earning","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/assessing-3sbio-sehk1530-valuation-after-strong-2025-earning","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","BK1593","DCF","HK0000165453.HKD","01530","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166924251","title":"Can Southbound Capital Propel 3SBIO's Stock Rebound Post-Earnings?","url":"https://stock-news.laohu8.com/highlight/detail?id=1166924251","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166924251?lang=en_us&edition=fundamental","pubTime":"2026-04-10 16:03","pubTimestamp":1775808231,"startTime":"0","endTime":"0","summary":"On May 20 last year, 3SBIO (01530) entered into a major business development (BD) transaction with Pfizer, with a total potential value exceeding $6 billion. The deal set a new record for upfront...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000165453.HKD","01530","BK1583","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198055679","title":"3SBio Sets 23 April 2026 Vote on In-Specie Dividend of Mandi Shares as Part of Planned Spin-Off","url":"https://stock-news.laohu8.com/highlight/detail?id=1198055679","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198055679?lang=en_us&edition=fundamental","pubTime":"2026-04-01 16:49","pubTimestamp":1775033354,"startTime":"0","endTime":"0","summary":"3SBio Inc. has issued a circular proposing a conditional special dividend to be executed through an in-specie distribution of all Mandi Inc. shares currently held by the group. The move is tied to...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111420823","title":"3SBio Convenes 23 April 2026 EGM to Ratify In-Specie Special Dividend of Full Mandi Inc. Shareholding","url":"https://stock-news.laohu8.com/highlight/detail?id=1111420823","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111420823?lang=en_us&edition=fundamental","pubTime":"2026-04-01 16:48","pubTimestamp":1775033320,"startTime":"0","endTime":"0","summary":"3SBio Inc. has scheduled an Extraordinary General Meeting (EGM) for 23 April 2026 at 10:00 a.m., to be held at the company’s headquarters in Shenyang, People’s Republic of China. The sole ordinary...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624956445","title":"3SBio announces extraordinary general meeting to approve Mandi shares distribution dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2624956445","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624956445?lang=en_us&edition=fundamental","pubTime":"2026-04-01 16:32","pubTimestamp":1775032372,"startTime":"0","endTime":"0","summary":"3SBio set an extraordinary general meeting in Shenyang, China on April 23, 2026.Shareholders will vote on declaring a conditional special dividend funded from share premium via an in-specie distribution of all Mandi shares held by 3SBio to qualifying shareholders.Resolution also seeks authorization for board to implement distribution, including setting record date, distribution basis, and mechanics for transferring Mandi shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 3SBio Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL1LCCl1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","HK0000165453.HKD","01530","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147015943","title":"Stock Track | 3SBIO Soars 11.66% Intraday as CICC Maintains Outperform Rating with 61% Upside Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1147015943","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147015943?lang=en_us&edition=fundamental","pubTime":"2026-04-01 14:29","pubTimestamp":1775024973,"startTime":"0","endTime":"0","summary":"3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.CICC maintained its Outperform rating on 3SBIO with a target price of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101073740","title":"CICC Maintains Outperform Rating on 3SBIO with HK$36.5 Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1101073740","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101073740?lang=en_us&edition=fundamental","pubTime":"2026-04-01 13:50","pubTimestamp":1775022646,"startTime":"0","endTime":"0","summary":"CICC has released a research report stating that, considering the timing of profit recognition from out-licensing revenue, it has lowered its net profit forecast for 3SBIO (01530) for 2026 by 47% to...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1593","EWH","HK0000165453.HKD","01530","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623973589","title":"3SBio - 2025 Adj Net Profit Attributable to Shareholders RMB 8.45 Bln, up 264.6% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2623973589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623973589?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:13","pubTimestamp":1774959180,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA38Q7SG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1593","HK0000165453.HKD","01530","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623589921","title":"3SBio - Declares 2025 Final Dividend of HKD 0.25 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2623589921","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623589921?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:13","pubTimestamp":1774959180,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA38Q7SG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","HK0000165453.HKD","BK1161","BK1583","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623589931","title":"3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2623589931","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623589931?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:13","pubTimestamp":1774959180,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc.  today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs in innovative R&D and strategic global collaboration, the company delivered a high-quality performance with both quantitative and qualitative growth: annual revenue hit RMB 17.7 billion, a historic breakthrough past the RMB 10 billion mark, representing a 94.3% year-on-year  increase; net profit attributable to shareholders of the parent company reached RMB 8.48 billion, surging 305.8% YoY; adjusted net profit attributable to shareholders of the parent company stood at RMB 8.45 billion, a 264.6% YoY rise. The company's profitability achieved a leap-forward growth, demonstrating robust growth momentum.Under the collaboration agreement, 3SBio granted Pfizer exclusive global development and commercialization rights to SSGJ-707, with the total potential deal value exceeding US$6 billion. The company is also entitled to tiered double-digi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/3sbio-announces-2025-annual-results-dual-engines-of-innovative-rd-and-global-collaboration-propel-revenue-past-rmb-10-billion-milestone-302729335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","HK0000165453.HKD","BK4007","IE00B19Z3581.USD","IE00BLSP4452.SGD","LU0170899867.USD","SG9999002232.USD","ITP","LU0289739699.SGD","LU0321505868.SGD","SG9999001176.USD","SG9999011175.SGD","IE0002270589.USD","BK4181","LU0225284248.USD","LU0985481810.HKD","SLE","IE000M9KFDE8.USD","SG9999003800.SGD","SAA","BK4534","LU1894683348.USD","BK4588","BK4077","LU1066053197.SGD","IBD","PFE","LU1883839398.USD","ADA.AU","IND.AU","SG9999013999.USD","BK4599","IE00B19Z3B42.SGD","BK1161","LU0456855351.SGD","BK1593","01530","BK7095","LU1894683264.USD","LU0321505439.SGD","CLDT","BRVO","BK4218","BK4592","BK1583","BK7016","BK4585","BK4581","LU0306806265.USD","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623132199","title":"3SBio (SEHK:1530) Valuation Check After Strong 2025 Sales And Earnings Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2623132199","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623132199?lang=en_us&edition=fundamental","pubTime":"2026-03-31 03:06","pubTimestamp":1774897576,"startTime":"0","endTime":"0","summary":"3SBio (SEHK:1530) just released full year 2025 results, reporting sales of CNY 17,695.75 million and net income of CNY 8,482.16 million, drawing fresh attention to the stock’s recent move.\nSee our latest analysis for 3SBio.\nThe earnings release follows a board meeting earlier in March that highlighted these results and a potential final dividend. The strong full year figures appear to align with fresh interest in the stock, with a 7 day share price return of 13.25% and a 1 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/3sbio-sehk1530-valuation-check-after-strong-2025-sales-and-e","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/3sbio-sehk1530-valuation-check-after-strong-2025-sales-and-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK1583","BK1593","BK1161","HK0000165453.HKD","01530"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":-0.105},{"period":"1month","weight":-0.0759},{"period":"3month","weight":-0.0797},{"period":"6month","weight":-0.2159},{"period":"1year","weight":0.7157},{"period":"ytd","weight":-0.0835}],"compareEarnings":[{"period":"1week","weight":-0.0165},{"period":"1month","weight":0.039},{"period":"3month","weight":-0.0443},{"period":"6month","weight":-0.016},{"period":"1year","weight":0.1795},{"period":"ytd","weight":0.0115}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"3SBio Inc is an investment holding company principally engaged in the development, production, marketing and sale of biopharmaceutical products. The Company's main products include biopharmaceuticals such as TPIAO, EPIAO, Yisaipu, and Cipterbin, as well as small moleculessuch as Mandi and Remitch. The Company is also engaged in the contract development and manufacturing operations (CDMO) business that provides customers with research, development and production of a variety of biopharmaceuticals and therapeutic technology platform services. The Company's products are mainly used for chemotherapy-induced thrombocytopenia (CIT), anemia caused by chronic kidney disease (CKD), treatment of chemotherapy-induced anemia (CIA), ankylosing spondylitis (AS) and psoriasis. The Company mainly operates its businesses in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.00666},{"month":2,"riseRate":0.454545,"avgChangeRate":0.00178},{"month":3,"riseRate":0.818182,"avgChangeRate":0.113214},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.015016},{"month":5,"riseRate":0.7,"avgChangeRate":0.109101},{"month":6,"riseRate":0.8,"avgChangeRate":0.036581},{"month":7,"riseRate":0.090909,"avgChangeRate":-0.038254},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.014022},{"month":9,"riseRate":0.636364,"avgChangeRate":0.027455},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.018307},{"month":11,"riseRate":0.727273,"avgChangeRate":0.059913},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.045323}],"exchange":"SEHK","name":"3SBIO","nameEN":"3SBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"3SBIO(01530),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest 3SBIO(01530) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"3SBIO,01530,3SBIO股票,3SBIO股票老虎,3SBIO股票老虎国际,3SBIO行情,3SBIO股票行情,3SBIO股价,3SBIO股市,3SBIO股票价格,3SBIO股票交易,3SBIO股票购买,3SBIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"3SBIO(01530),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest 3SBIO(01530) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}